Cancer
Malignant Kidney Neoplasm
CI-CAN-00003171Explore in graph →
Top-level453 active trials17 approved drugs80 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003171Explore in graph →
Clinical trials
2,142 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (339)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06917560 | Serological Autoantibodies in Early Kidney Cancer Diagnosis and Prognosis: A Multicenter Study | active not recruiting | — | 400 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT03647163 | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 33 | Vyriad, Inc.INDUSTRY | 1 | Sep 16, 2025 |
| clinicaltrials |
| NCT04163289 | Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation(PERFORM) | active not recruiting | Phase 1 | 20 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT05871008 | Integrated Actionable Aging Assessment for Cancer Patients Pilot | active not recruiting | N/A | 35 | University of Colorado, DenverOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07173140 | Renal Tumour Imaging Using MRI(RIM) | active not recruiting | N/A | 30 | University College, LondonOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT03937219 | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(COSMIC-313) | active not recruiting | Phase 3 | 855 | ExelixisINDUSTRY | 25 | Sep 10, 2025 | clinicaltrials |
| NCT05653882 | A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | active not recruiting | Phase 1 | 552 | Asher Biotherapeutics, Inc.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05782400 | Multiomics Approach in Metastatic Clear Renal Cell Carcnoma | active not recruiting | — | 100 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06127238 | Study of ST-1898 in Advanced Renal Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 90 | Beijing Scitech-Mq Pharmaceuticals LimitedINDUSTRY | 1 | Aug 24, 2025 | clinicaltrials |
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 914 | ExelixisINDUSTRY | 9 | Aug 17, 2025 | clinicaltrials |
| NCT04522323 | A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma | active not recruiting | Phase 1 | 67 | MedImmune LLCINDUSTRY | 4 | Jul 25, 2025 | clinicaltrials |
| NCT07060248 | A Study Based on CT Radiomics for Distinguishing Benign From Malignant Renal Tumors and Assessing Their Aggressiveness. | active not recruiting | — | 700 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT07047001 | Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma | active not recruiting | Phase 2 | 60 | Dong WenOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT05286294 | Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders(MITRIC) | active not recruiting | Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT05887245 | Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy | active not recruiting | — | 200 | Centre of Postgraduate Medical EducationOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT05219318 | Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors(SPICI) | active not recruiting | Phase 3 | 22 | University Hospital, BordeauxOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT04120805 | Random Evaluation of Patients Who Have Had Laparoscopic Partial Nephrectomy | active not recruiting | N/A | 178 | University of ChicagoOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT05704985 | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | active not recruiting | Phase 1 | 39 | DEKA BiosciencesINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT05179824 | Tempus Priority Study: A Pan-tumor Observational Study | active not recruiting | — | 1,000 | Tempus AIINDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 272 | Checkpoint Therapeutics, Inc.INDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT05522231 | Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) | active not recruiting | Phase 2 / Phase 3 | 265 | HutchmedINDUSTRY | 1 | Jan 3, 2025 | clinicaltrials |
| NCT03634540 | A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) | active not recruiting | Phase 2 | 118 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT05128487 | A Study of NDI 1150-101 in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 106 | Nimbus Saturn, Inc.INDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT03845166 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors(STELLAR-001) | active not recruiting | Phase 1 | 325 | ExelixisINDUSTRY | 10 | Nov 19, 2024 | clinicaltrials |
| NCT05199272 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | active not recruiting | Phase 1 / Phase 2 | 141 | 23andMe, Inc.INDUSTRY | 2 | Nov 15, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT02293980 | A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) | active not recruiting | Phase 1 | 110 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jun 17, 2024 | clinicaltrials |
| NCT03501381 | High Dose IL 2 and Entinostat in RCC | active not recruiting | Phase 2 | 46 | Roberto PiliOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT03308396 | Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | Ajjai Alva, MDOTHER | 1 | Feb 17, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Sep 18, 2025source: clinicaltrials